Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ICAM-1 and VCAM-1 antagonists
Autore:
Richards, IM; Slatter, VK;
Indirizzi:
Pharmacia Corp, Kalamazoo, MI 49001 USA Pharmacia Corp Kalamazoo MI USA 49001 macia Corp, Kalamazoo, MI 49001 USA
Titolo Testata:
NEW DRUGS FOR ASTHMA, ALLERGY AND COPD
, volume: 31, anno: 2001,
pagine: 310 - 313
SICI:
1422-2140(2001)31:<310:IAVA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTERCELLULAR-ADHESION MOLECULE-1; OBSTRUCTIVE PULMONARY-DISEASE; SEGMENTAL ANTIGEN CHALLENGE; AIRWAY LUMEN; EXPRESSION; ASTHMA; LYMPHOCYTES;
Tipo documento:
Article
Natura:
Collana
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Richards, IM Pharmacia Corp, 301 Henrietta St, Kalamazoo, MI 49001 USA Pharmacia Corp 301 Henrietta St Kalamazoo MI USA 49001 01 USA
Citazione:
I.M. Richards e V.K. Slatter, "ICAM-1 and VCAM-1 antagonists", PROG R RES, 31, 2001, pp. 310-313

Abstract

The accumulation and activation of inflammatory cells in the respiratory tract in asthma and COPD is critically dependent on the ordered expression of specific adhesion molecules on subsets of leukocytes, and the expression of counter-receptors, such as intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106) on endothelial cells. ICAM-1 and VCAM-1 can also be selectively expressed on other cell types in the lungs, e.g. epithelial cells (ICAM-1), fibroblasts (ICAM-1 and VCAM-1) and T lymphocytes (ICAM-1). Products of activated eosinophils and neutrophils within the airway wall cause epithelial damage which results in airway hyperresponsiveness. Some known anti-inflammatory agents such as glucocorticoids have been shown to inhibit the expression of VCAM-1 and ICAM-1 inthe lungs and respiratory tract. Novel agents directed towards blocking VCAM-1 or ICAM-1 specifically, and currently in preclinical and clinical development, have been described and include monoclonal antibodies, soluble forms of ICAM-1 and VCAM-1, oligonucleotides (antisense) and small molecules. However, to date none of these approaches have yielded an agent in late stage clinical development.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 12:21:24